{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T20:33:14Z","timestamp":1761856394845,"version":"build-2065373602"},"reference-count":49,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,1,11]],"date-time":"2022-01-11T00:00:00Z","timestamp":1641859200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013362","name":"Swiss Cancer Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013362","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008349","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008349","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011725","name":"Servier","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100011725","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["esmoopen.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["ESMO Open"],"published-print":{"date-parts":[[2022,4]]},"DOI":"10.1016\/j.esmoop.2022.100392","type":"journal-article","created":{"date-parts":[[2022,2,16]],"date-time":"2022-02-16T02:31:09Z","timestamp":1644978669000},"page":"100392","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["ESMO Congress 2021: highlights from the EORTC gastrointestinal tract cancer group\u2019s perspective"],"prefix":"10.1016","volume":"7","author":[{"given":"T.","family":"Koessler","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Alsina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Arnold","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I.","family":"Ben-Aharon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Collienne","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.P.","family":"Lutz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Neuzillet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Obermannova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Peeters","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Sclafani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Smyth","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.W.","family":"Valle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.D.","family":"Wagner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Wyrwicz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Fontana","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Moehler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.esmoop.2022.100392_bib1","doi-asserted-by":"crossref","first-page":"S1329","DOI":"10.1016\/j.annonc.2021.08.2131","article-title":"LBA7 Nivolumab (NIVO) plus chemotherapy (Chemo) or ipilimumab (IPI) vs chemo as first-line (1L) treatment for advanced gastric cancer\/gastroesophageal junction cancer\/esophageal adenocarcinoma (GC\/GEJC\/EAC): CheckMate 649 study","volume":"32","author":"Janjigian","year":"2021","journal-title":"Ann Oncol"},{"key":"10.1016\/j.esmoop.2022.100392_bib2","doi-asserted-by":"crossref","first-page":"S1331","DOI":"10.1016\/j.annonc.2021.08.2134","article-title":"LBA54 Ipilimumab or FOLFOX in combination with nivolumab and trastuzumab in previously untreated HER2 positive locally advanced or metastastic esophagogastric adenocarcinoma (EGA): results of the randomized phase II INTEGA trial (AIO STO 0217)","volume":"32","author":"Stein","year":"2021","journal-title":"Ann Oncol"},{"key":"10.1016\/j.esmoop.2022.100392_bib3","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/S0140-6736(10)61121-X","article-title":"Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial","volume":"376","author":"Bang","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.esmoop.2022.100392_bib4","doi-asserted-by":"crossref","first-page":"S1043","DOI":"10.1016\/j.annonc.2021.08.1488","article-title":"1379P Margetuximab (M) with retifanlimab (R) in HER2+, PD-L1+ 1st-line unresectable\/metastatic gastroesophageal adenocarcinoma (GEA): MAHOGANY cohort A","volume":"32","author":"Catenacci","year":"2021","journal-title":"Ann Oncol"},{"key":"10.1016\/j.esmoop.2022.100392_bib5","doi-asserted-by":"crossref","first-page":"S1330","DOI":"10.1016\/j.annonc.2021.08.2132","article-title":"LBA52 Sintilimab plus chemotherapy versus chemotherapy as first-line therapy in patients with advanced or metastatic esophageal squamous cell cancer: first results of the phase III ORIENT-15 study","volume":"32","author":"Shen","year":"2021","journal-title":"Ann Oncol"},{"key":"10.1016\/j.esmoop.2022.100392_bib6","doi-asserted-by":"crossref","first-page":"S1331","DOI":"10.1016\/j.annonc.2021.08.2133","article-title":"LBA53 Sintilimab plus chemotherapy (chemo) versus chemo as first-line treatment for advanced gastric or gastroesophageal junction (G\/GEJ) adenocarcinoma (ORIENT-16): first results of a randomized, double-blind, phase III study","volume":"32","author":"Xu","year":"2021","journal-title":"Ann Oncol"},{"key":"10.1016\/j.esmoop.2022.100392_bib7","doi-asserted-by":"crossref","first-page":"S1040","DOI":"10.1016\/j.annonc.2021.08.1481","article-title":"1372O CLDN 18.2-targeted CAR-T cell therapy in patients with cancers of the digestive system","volume":"32","author":"Qi","year":"2021","journal-title":"Ann Oncol"},{"key":"10.1016\/j.esmoop.2022.100392_bib8","doi-asserted-by":"crossref","first-page":"S1332","DOI":"10.1016\/j.annonc.2021.08.2135","volume":"32","author":"van Cutsem","year":"2021","journal-title":"Ann Oncol"},{"key":"10.1016\/j.esmoop.2022.100392_bib9","doi-asserted-by":"crossref","first-page":"2419","DOI":"10.1056\/NEJMoa2004413","article-title":"Trastuzumab deruxtecan in previously treated HER2-positive gastric cancer","volume":"382","author":"Shitara","year":"2020","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.esmoop.2022.100392_bib10","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2018.36.15_suppl.3502","article-title":"Modified FOLFOX6 with or without radiation in neoadjuvant treatment of locally advanced rectal cancer: Final results of the Chinese FOWARC multicenter randomized trial","volume":"36","author":"Deng","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.esmoop.2022.100392_bib11","doi-asserted-by":"crossref","first-page":"S1296","DOI":"10.1016\/j.annonc.2021.08.2096","volume":"32","author":"Ding","year":"2021","journal-title":"Ann Oncol"},{"key":"10.1016\/j.esmoop.2022.100392_bib12","doi-asserted-by":"crossref","first-page":"S1294","DOI":"10.1016\/j.annonc.2021.08.2094","article-title":"LBA20 FOLFOXIRI plus bevacizumab (bev) plus atezolizumab (atezo) versus FOLFOXIRI plus bev as first-line treatment of unresectable metastatic colorectal cancer (mCRC) patients: results of the phase II randomized AtezoTRIBE study by GONO","volume":"32","author":"Cremolini","year":"2021","journal-title":"Ann Oncol"},{"key":"10.1016\/j.esmoop.2022.100392_bib13","doi-asserted-by":"crossref","first-page":"S1295","DOI":"10.1016\/j.annonc.2021.08.2095","article-title":"LBA21 Radioembolization with chemotherapy for colorectal liver metastases: a randomized, open-label, international, multicenter, phase III trial (EPOCH study)","volume":"32","author":"Mulcahy","year":"2021","journal-title":"Ann Oncol"},{"key":"10.1016\/j.esmoop.2022.100392_bib14","doi-asserted-by":"crossref","first-page":"S530","DOI":"10.1016\/j.annonc.2021.08.905","article-title":"383O MAYA trial: Temozolomide (TMZ) priming followed by combination with low-dose ipilimumab and nivolumab in patients with microsatellite stable (MSS), MGMT silenced metastatic colorectal cancer (mCRC)","volume":"32","author":"Pietrantonio","year":"2021","journal-title":"Ann Oncol"},{"key":"10.1016\/j.esmoop.2022.100392_bib15","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1056\/NEJMoa1917239","article-title":"KRASG12C inhibition with sotorasib in advanced solid tumors","volume":"383","author":"Hong","year":"2020","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.esmoop.2022.100392_bib16","doi-asserted-by":"crossref","first-page":"S1294","DOI":"10.1016\/j.annonc.2021.08.2093","article-title":"LBA6 KRYSTAL-1: Adagrasib (MRTX849) as monotherapy or combined with cetuximab (Cetux) in patients (Pts) with colorectal cancer (CRC) harboring a KRASG12C mutation","volume":"32","author":"Weiss","year":"2021","journal-title":"Ann Oncol"},{"key":"10.1016\/j.esmoop.2022.100392_bib17","doi-asserted-by":"crossref","first-page":"S551","DOI":"10.1016\/j.annonc.2021.08.955","article-title":"434P CodeBreaK 101 subprotocol H: Phase Ib study evaluating combination of sotorasib (Soto), a KRASG12C inhibitor, and panitumumab (PMab), an EGFR inhibitor, in advanced KRAS p.G12C-mutated colorectal cancer (CRC)","volume":"32","author":"Fakih","year":"2021","journal-title":"Ann Oncol"},{"key":"10.1016\/j.esmoop.2022.100392_bib18","doi-asserted-by":"crossref","first-page":"S530","DOI":"10.1016\/j.annonc.2021.08.904","article-title":"382O Inhibition of WEE1 is effective in TP53 and RAS mutant metastatic colorectal cancer (mCRC): a randomised phase II trial (FOCUS4-C) comparing adavosertib (AZD1775) with active monitoring","volume":"32","author":"Seligmann","year":"2021","journal-title":"Ann Oncol"},{"key":"10.1016\/j.esmoop.2022.100392_bib19","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1016\/S1470-2045(21)00086-3","article-title":"Trastuzumab deruxtecan (DS-8201) in patients with HER2-expressing metastatic colorectal cancer (DESTINY-CRC01): a multicentre, open-label, phase 2 trial","volume":"22","author":"Siena","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.esmoop.2022.100392_bib20","doi-asserted-by":"crossref","first-page":"S532","DOI":"10.1016\/j.annonc.2021.08.908","article-title":"386O Exploratory biomarker analysis of DESTINY-CRC01, a phase II, multicenter, open-label study of trastuzumab deruxtecan (T-DXd, DS-8201) in patients (pts) with HER2-expressing metastatic colorectal cancer (mCRC)","volume":"32","author":"Siena","year":"2021","journal-title":"Ann Oncol"},{"key":"10.1016\/j.esmoop.2022.100392_bib21","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/S0140-6736(21)00153-7","article-title":"Biliary tract cancer","volume":"397","author":"Valle","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.esmoop.2022.100392_bib22","doi-asserted-by":"crossref","first-page":"S1282","DOI":"10.1016\/j.annonc.2021.08.2082","article-title":"LBA10 Nal-IRI with 5-fluorouracil (5-FU) and leucovorin or gemcitabine plus cisplatin in advanced biliary tract cancer: Final results of the NIFE-trial (AIO-YMO HEP-0315), a randomized phase II study of the AIO biliary tract cancer group","volume":"32","author":"Perkhofer","year":"2021","journal-title":"Ann Oncol"},{"key":"10.1016\/j.esmoop.2022.100392_bib23","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/S0140-6736(15)00986-1","article-title":"Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial","volume":"387","author":"Wang-Gillam","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.esmoop.2022.100392_bib24","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2021.39.15_suppl.4006","article-title":"Liposomal irinotecan (nal-IRI) in combination with fluorouracil (5-FU) and leucovorin (LV) for patients with metastatic biliary tract cancer (BTC) after progression on gemcitabine plus cisplatin (GemCis): multicenter comparative randomized phase 2b study","volume":"39","author":"Yoo","year":"2021","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.esmoop.2022.100392_bib25","doi-asserted-by":"crossref","first-page":"S621","DOI":"10.1016\/j.annonc.2021.08.702","article-title":"567O First international randomized study in malignant progressive pheochromocytoma and paragangliomas\u00a0(FIRSTMAPPP): an academic double-blind trial investigating sunitinib","volume":"32","author":"Baudin","year":"2021","journal-title":"Ann Oncol"},{"key":"10.1016\/j.esmoop.2022.100392_bib26","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1056\/NEJMoa1003825","article-title":"Sunitinib malate for the treatment of pancreatic neuroendocrine tumors","volume":"364","author":"Raymond","year":"2011","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.esmoop.2022.100392_bib27","doi-asserted-by":"crossref","first-page":"S906","DOI":"10.1016\/j.annonc.2021.08.178","article-title":"1096O Lanreotide autogel\/depot (LAN) in patients with advanced bronchopulmonary (BP) neuroendocrine tumors (NETs): results from the phase III SPINET study","volume":"32","author":"Baudin","year":"2021","journal-title":"Ann Oncol"},{"key":"10.1016\/j.esmoop.2022.100392_bib28","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1056\/NEJMoa1316158","article-title":"Lanreotide in metastatic enteropancreatic neuroendocrine tumors","volume":"371","author":"Caplin","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.esmoop.2022.100392_bib29","doi-asserted-by":"crossref","first-page":"4656","DOI":"10.1200\/JCO.2009.22.8510","article-title":"Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID study group","volume":"27","author":"Rinke","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.esmoop.2022.100392_bib30","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2021.39.3_suppl.360","article-title":"A\u00a0phase II\/III randomized double-blind study of octreotide acetate LAR with axitinib versus octreotide acetate LAR with placebo in patients with advanced G1-G2 NETs of non-pancreatic origin (AXINET trial-GETNE-1107)","volume":"39","author":"Garcia-Carbonero","year":"2021","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.esmoop.2022.100392_bib31","doi-asserted-by":"crossref","first-page":"S907","DOI":"10.1016\/j.annonc.2021.08.179","article-title":"1097O the AXINET trial (GETNE1107): axitinib plus octreotide LAR improves PFS by blinded central radiological assessment vs placebo plus octreotide LAR in G1-2 extrapancreatic NETs","volume":"32","author":"Garcia-Carbonero","year":"2021","journal-title":"Ann Oncol"},{"key":"10.1016\/j.esmoop.2022.100392_bib32","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1200\/JCO.19.02274","article-title":"Preoperative chemoradiotherapy versus immediate surgery for resectable and borderline resectable pancreatic cancer: results of the Dutch randomized phase III PREOPANC trial","volume":"38","author":"Versteijne","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.esmoop.2022.100392_bib33","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2021.39.15_suppl.4016","article-title":"Preoperative chemoradiotherapy to improve overall survival in pancreatic cancer: long-term results of the multicenter randomized phase III PREOPANC trial","volume":"39","author":"Van Eijck","year":"2021","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.esmoop.2022.100392_bib34","doi-asserted-by":"crossref","first-page":"S1283","DOI":"10.1016\/j.annonc.2021.08.2136","article-title":"LBA56 Perioperative or only adjuvant nab-paclitaxel plus gemcitabine for resectable pancreatic cancer: results of the NEONAX trial, a randomized phase II AIO study","volume":"32","author":"Seufferlein","year":"2021","journal-title":"Ann Oncol"},{"key":"10.1016\/j.esmoop.2022.100392_bib35","doi-asserted-by":"crossref","first-page":"S226","DOI":"10.1016\/j.annonc.2021.06.009","article-title":"LBA-1 Phase 3 APACT trial of adjuvant nab-paclitaxel plus gemcitabine (nab-P\u00a0+ Gem) vs gemcitabine (Gem) alone in patients with resected pancreatic cancer (PC): updated 5-year overall survival","volume":"32","author":"Tempero","year":"2021","journal-title":"Ann Oncol"},{"key":"10.1016\/j.esmoop.2022.100392_bib36","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1056\/NEJMoa1809775","article-title":"FOLFIRINOX or gemcitabine as adjuvant therapy for pancreatic cancer","volume":"379","author":"Conroy","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.esmoop.2022.100392_bib37","doi-asserted-by":"crossref","first-page":"S1334","DOI":"10.1016\/j.annonc.2021.08.2137","article-title":"LBA57 Unicancer PRODIGE 24\/CCTG PA6 trial: updated results of a multicenter international randomized phase III trial of adjuvant mFOLFIRINOX (mFFX) versus gemcitabine (gem) in patients (pts) with resected pancreatic ductal adenocarcinomas (PDAC)","volume":"32","author":"Conroy","year":"2021","journal-title":"Ann Oncol"},{"key":"10.1016\/j.esmoop.2022.100392_bib38","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1200\/JCO.2013.50.7657","article-title":"Optimal duration and timing of adjuvant chemotherapy after definitive surgery for ductal adenocarcinoma of the pancreas: ongoing lessons from the ESPAC-3 study","volume":"32","author":"Valle","year":"2014","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.esmoop.2022.100392_bib39","doi-asserted-by":"crossref","first-page":"S1210","DOI":"10.1016\/j.annonc.2021.08.1703","article-title":"1758O Neoadjuvant pembrolizumab in localized\/locally advanced solid tumors with mismatch repair deficiency","volume":"32","author":"Ludford","year":"2021","journal-title":"Ann Oncol"},{"key":"10.1016\/j.esmoop.2022.100392_bib40","doi-asserted-by":"crossref","first-page":"S910","DOI":"10.1016\/j.annonc.2021.08.182","article-title":"1100MO Molecular characteristics of high-grade gastroenteropancreatic neuroendocrine neoplasms","volume":"32","author":"Sorbye","year":"2021","journal-title":"Ann Oncol"},{"key":"10.1016\/j.esmoop.2022.100392_bib41","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1038\/nature13480","article-title":"Comprehensive molecular characterization of gastric adenocarcinoma","volume":"513","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.esmoop.2022.100392_bib42","doi-asserted-by":"crossref","first-page":"S1069","DOI":"10.1016\/j.annonc.2021.08.1539","volume":"32","author":"Kopp","year":"2021","journal-title":"Ann Oncol"},{"key":"10.1016\/j.esmoop.2022.100392_bib43","doi-asserted-by":"crossref","first-page":"S1069","DOI":"10.1016\/j.annonc.2021.08.1538","volume":"32","author":"Al-Batran","year":"2021","journal-title":"Ann Oncol"},{"key":"10.1016\/j.esmoop.2022.100392_bib44","doi-asserted-by":"crossref","first-page":"S1070","DOI":"10.1016\/j.annonc.2021.08.1540","article-title":"1431P Descriptive analysis and prognostic factors of microsatellite instability (MSI) gastric cancer patients (pts) compared to microsatellite stable (MSS) pts in a tertiary hospital","volume":"32","author":"Mirallas","year":"2021","journal-title":"Ann Oncol"},{"key":"10.1016\/j.esmoop.2022.100392_bib45","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1038\/nrgastro.2016.51","article-title":"Expert consensus document: cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA)","volume":"13","author":"Banales","year":"2016","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.esmoop.2022.100392_bib47","doi-asserted-by":"crossref","first-page":"S512","DOI":"10.1016\/j.annonc.2021.08.617","article-title":"334TiP A phase I trial of niraparib plus anlotinib in advanced solid tumors with homologous recombination repair (HRR) gene mutations","volume":"32","author":"Zhang","year":"2021","journal-title":"Ann Oncol"},{"key":"10.1016\/j.esmoop.2022.100392_bib48","doi-asserted-by":"crossref","first-page":"S376","DOI":"10.1016\/j.annonc.2021.08.326","article-title":"47P Derazantinib for patients with intrahepatic cholangiocarcinoma harboring FGFR2 fusions\/rearrangements: primary results from the phase II study FIDES-01","volume":"32","author":"Busset","year":"2021","journal-title":"Ann Oncol"},{"key":"10.1016\/j.esmoop.2022.100392_bib49","doi-asserted-by":"crossref","first-page":"S1073","DOI":"10.1016\/j.annonc.2021.08.1546","article-title":"1437TiP Phase Ib\/II, open label, dose escalation and expansion trial of tucatinib in combination with trastuzumab and oxaliplatin-based chemotherapy in patients with unresectable or metastatic HER2+ gastrointestinal cancers (trial in Progress)","volume":"32","author":"Park","year":"2021","journal-title":"Ann Oncol"},{"key":"10.1016\/j.esmoop.2022.100392_bib50","doi-asserted-by":"crossref","first-page":"S1255","DOI":"10.1016\/j.annonc.2021.08.758","article-title":"1871TiP PLATON \u2013 \u201cPlatform for analyzing targetable tumor mutations\u201d: a pilot study","volume":"32","author":"Vogel","year":"2021","journal-title":"Ann Oncol"}],"container-title":["ESMO Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702922000126?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702922000126?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T20:28:18Z","timestamp":1761856098000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2059702922000126"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4]]},"references-count":49,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,4]]}},"alternative-id":["S2059702922000126"],"URL":"https:\/\/doi.org\/10.1016\/j.esmoop.2022.100392","relation":{},"ISSN":["2059-7029"],"issn-type":[{"type":"print","value":"2059-7029"}],"subject":[],"published":{"date-parts":[[2022,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"ESMO Congress 2021: highlights from the EORTC gastrointestinal tract cancer group\u2019s perspective","name":"articletitle","label":"Article Title"},{"value":"ESMO Open","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.esmoop.2022.100392","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}],"article-number":"100392"}}